Breaking News Bar

Business News and Information

Can a Nimble FDA Help Your Portfolio ETFs?

By: ETFdb
The Food and Drug Administration (FDA) appears likely to be active on the drug review front in the months, with COVID-19 in the way. Expect that activity could benefit exchange traded funds with exposure to small- and mid-cap biotechnology stocks, including the ALPS Medical Breakthroughs ETF ( SBIO ).
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear